Anthony J. Krick - Mar 8, 2023 Form 4 Insider Report for OptiNose, Inc. (OPTN)

Signature
/s/ Anthony Krick
Stock symbol
OPTN
Transactions as of
Mar 8, 2023
Transactions value $
$0
Form type
4
Date filed
3/10/2023, 01:41 PM
Previous filing
Jun 10, 2022
Next filing
Feb 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OPTN Common Stock Award $0 +33.8K $0.00 33.8K Mar 8, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OPTN Stock Option (Right to Buy) Award $0 +50.8K $0.00 50.8K Mar 8, 2023 Common Stock 50.8K $1.90 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on March 8, 2024, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer provided that, in the event XHANCE is approved by the U.S. FDA for commercialization for the treatment of chronic rhinosinusitis or substantially similar indication, then any unvested RSUs shall become fully-vested on the four month anniversary of such approval, subject to the Executive's continued service through such date. Each RSU represents the right to receive one share of common stock of OptiNose, Inc.
F2 The option vests and becomes exercisable over a four-year period commencing on March 8, 2023. Twenty-five percent (25%) of the option vests and becomes exercisable on March 8, 2024, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.